INCREASED PHOSPHORYLATION OF DARPP-32 BY D_1 AGONISTIC ACTION OF l-STEPHOLIDINE IN THE 6-OHDA-LESIONED RAT STRIATUM

为了进一步阐明ＳＰＤ对大鼠纹状体突触后Ｄ１受体的激动作用特性,本文应用反磷酸化在体内测定及放射配体结合方法,分别观察ＳＰＤ对６ＯＨＤＡ损毁大鼠纹状体ＤＡＲＰＰ３２体内磷酸化作用及突触后Ｄ１受体密度的影响。结果表明：皮下给予ＳＰＤ（２０,４０ｍｇ／ｋｇ,２１ｄ）,损毁侧纹状体ＤＡＲＰＰ３２体外［３２Ｐ］的掺入量较健侧下降５０％（Ｐ＜００１）。换言之,损毁侧纹状体内ＤＡＲＰＰ３２的磷酸化程度增加了。然而,ＳＰＤ使损毁导致Ｄ１受体上调的作用减弱（Ｂｍａｘ从３８５０±２６１ｆｍｏｌ／ｍｇ降至３１９７±２０１ｆｍｏｌ／ｍｇ水平）。因此,ＳＰＤ激动Ｄ１受体,使６ＯＨＤＡ损毁大鼠纹状体内ＤＡＲＰＰ３２磷酸化作用加强,而受体密度减少。这是ＳＰＤ调节脑内Ｄ１受体信号转导功能的重要机制。     

强啡肽对纹状体内D_1多巴胺受体反应的调节

用6-羟多巴胺破坏黑质纹状体通路,使大鼠多巴胺耗竭后,应用原位杂交组织化学方法测量D1多巴胺受体对即早基因c－fos和zif268诱导反应,分析强啡肽对突触前、后调节作用。先用D1多巴胺受体激动剂SKF－38393反复处理动物,促进纹状体内强啡肽表达,在伏隔核强啡肽表达增加,同时伴随着即早基因c-fos和zif268的减少．在纹状体的背部和两侧,强啡肽表达虽大量增加,而D1多巴胺受体反应仍然维持原水平．在中央纹状体区,即早基因的表达处于中间水平。结果提示,纹状体内强啡肽起着调节多巴胺输入到纹状体黑质神经元的作用,包括突触前、后位置;并且调节作用在纹状体的腹、背侧区是不同的     

左旋千金藤啶碱D_1激动-D_2 阻滞作用引起伏核双相放电活动的电生理研究(英文)

为确定左旋千金藤啶碱 (SPD)对中脑边缘DA神经系统的作用特性 ,本研究采用细胞外记录的电生理学方法 ,观察微电泳和尾静脉给药对 6 OHDA损毁及未损毁大鼠的伏核 (NAc)单位放电的影响。结果显示 :SPD累积给药 ( 0 0 2～ 2mg/kg,iv)可诱发NAc神经元双相放电特征 ,即小剂量抑制、大剂量兴奋。预先给予D2 受体拮抗剂spiperone ,SPD则仅产生兴奋效应 ,并被D1拮抗剂SCH 2 3390所翻转或阻断 ,提示SPD对NAc神经元放电有D1激动特性。另一方面 ,大剂量SPD完全翻转D2 激动剂LY 1715 5 5和D1/D2 混合型激动剂阿朴吗啡对NAc神经元的抑制作用 ,表明SPD还具有D2 受体的阻滞特性。与静脉给药不同 ,NAc内微电泳SPD ( 30mmol/L ,2 0～ 80nA)很难诱发该神经核的兴奋或抑制性放电 ,而微电泳D1激动剂SKF 38393能产生明显的放电抑制效应。然而 ,在 6 OHDA损毁大鼠 ,微电泳SPD可使绝大多数NAc神经元 ( 91% )放电抑制 ,并为D1阻滞剂SCH 2 3390所完全拮抗 ,而不受D2 阻滞剂spiperone的影响。以上结果表明 ,SPD对NAc神经元活动具有‘D2 阻滞 D1激动’的双重药理作用特性 ,后者与SPD作用于mPFC的D1受体有密切关系 ,这有利于治疗精神分裂症     

6-羟多巴胺纹状体内注射制作大鼠帕金森病模型的研究

目的 为拓宽6-OHDA损毁多巴胺能神经元所制备大鼠帕金森病模型的应用范围,采用多位点纹状体内注入6-OHDA的途径来制备模型。方法 研究用SD大鼠,两个针道内四点定位注射,每点注射3μg／μ16-OHDA3μl。结果 术后两周出现缓慢旋转,4周旋转行为达到7转／分并保持稳定;形态学染色可见损毁1周后注射侧黑质酪氨酸羟化酶免疫组化阳性细胞减少20％,2周后减少38％,3～4周减少70％以上,6周后损伤趋缓。高效液相-电化学法活体检测纹状体内多巴胺的代谢产物3、4-二羟基苯乙酸(DOPAC)和高香草酸(HVA),发现注射侧和非注射侧相比含量分别下降98．33％和96．05％;组织匀浆检测损毁侧黑质多巴胺含量下降了73％以上,3、4-二羟基苯乙酸(DOPAC)含量下降60％。结论 纹状体内注射6-OHDA能够制备帕金森病大鼠模型。     

阴虚动风证帕金森病异动症大鼠大麻素CB1受体变化及复方地黄方的干预作用

目的探讨阴虚动风证帕金森病(PD)异动症(LID)大鼠纹状体内大麻素CB1受体的表达及复方地黄方的干预作用。方法采用6-羟基多巴胺(6-OHDA)偏侧损毁黑质制备帕金森病大鼠模型,进一步腹腔注射左旋多巴+苄丝肼(50 mg/kg左旋多巴和12.5 mg/kg苄丝肼)制备LID大鼠模型,并随机分为LID组、复方地黄方组,另取正常对照组、假手术组大鼠为对照,每组6只。分别在4周、6周进行神经行为学检测后,处死大鼠并取纹状体,应用Western blot法测定各组大鼠纹状体内大麻素CB1受体的表达情况。结果 LID大鼠随造模时间延长,AIM评分呈增加趋势(P0.05),旋转启动时间呈缩短趋势(P0.05),旋转持续时间呈增加趋势(P0.01),剂峰旋转圈数呈减少趋势(P0.05),复方地黄方可改善上述变化。LID大鼠大麻素CB1受体表达增加,且随造模时间延长呈现减少趋势(P0.01),而复方地黄方干预后大麻素CB1受体的表达呈现逐渐增加的趋势(P0.01)。结论LID模型大鼠大麻素CB1受体的含量明显升高,其变化能够较好的反映阴虚动风证的严重程度,复方地黄方干预LID模型大鼠可能是通过激活纹状体内大麻素CB1受体,抑制兴奋性氨基酸(主要是谷氨酸)的释放和诱导细胞发生级联反应来减弱神经元的兴奋性,从而起到减轻L-dopa的兴奋毒性的作用。     

DARPP—32的结构,功能及其调节机制

DARPP-32是一种多巴胺（DA）和cAMP调节的磷蛋白，存在于所有接受DA能投射的神经元中，在中枢神经系统的分布与DAD1受体的分布非常一致。DA通过D1受体使DARPP-32第34位苏氨酸磷酸化，磷酸化DARPP-32成为蛋白磷酸酶1（PP-1）的强效抑制剂，在两个不同位点与PP-1相互作用，从而抑制PP-1活性。DARPP-32／PP-1级联反应在调节，如钙通道、电压依赖性钠通道、Na＋,K＋-ATPase和NMDANR1受体的功能等神经元兴奋性过程中起重要作用。DA对DARPP—32的磷酸化状态有双向调节作用，其他许多神经递质亦可调节其磷酸化状态。     

胎脑黑质脑内移植矫正PD鼠纹状体内脑啡肽mRNA过度表达

用６－ＯＨＤＡ损毁大鼠一侧黑质—纹状体通路可引起ＰＤ模型鼠脑纹状体内多巴胺匿乏．同时,亦可导致脑啡肽ｍＲＮＡ过度表达。我们用地高辛标记的ｃＲＮＡ探针对纹状体内脑啡肽ｍＲＮＡ含量进行了斑点杂交定量研究,发现损伤侧脑啡肽ｍＲＮＡ含量较健侧增高８０％,胎中脑移植到失神经支配的纹状体内,脑啡肽ｍＲＮＡ过度表达得以矫正至正常水平,说明胎多巴胺能神经元脑内移植能够调节脑啡肽基因表达,提供了移植物能与宿主发生神经整合、建立突触联系的间接证据。     

多巴胺能神经可能与调节性磷酸蛋白有功能联系

大鼠新皮质(NC)和新纹状体(NS)组织匀浆中存在内源性蛋白质磷酸化系统。无论有无cAMP,先将匀浆用[r-~(32)P]ATP和Mg~(2+)孵育,再用电泳分离和干乳胶放射自显影方法,得到一种磷酸蛋白,分子量为32000(32K)。多巴胺(DP)敏感性神经元(具有D-1受体——与腺苷酸环化酶相关的DP受体)中富含这种磷酸蛋白,其磷酸化过程受DP和cAMP调节,作者称之为多巴胺-和cAMP-调节性磷酸蛋白(DARPP—32)。分离过程中,作者发现DARPP-32可通过改良的酸提取技术,从NS匀浆中得到。有cAMP依赖式蛋白激酶催化亚基存在,运用上述技术也可获得DARPP-32和另一种磷酸蛋白Synapsin I(SI,即蛋白质I)。     

选择性5-HT1A受体拮抗剂WAY-100635增加6-羟多巴胺损毁大鼠杏仁基底外侧核的神经活动

本文采用玻璃微电极细胞外记录法,观察正常大鼠和6-羟多巴胺(6-hydroxydopamine,6-OHDA)损毁黑质致密部大鼠杏仁基底外侧核(basolateral nucleus,BL)神经元电活动的变化,以及体循环给予选择性5-HT1A受体拮抗剂WAY-100635对神经元电活动的影响.结果显示,正常大鼠BL投射神经元和中间神经元的放电频率分别足(O.39±0.04)Hz和(0.83±0.16)Hz,6-OHDA损毁大鼠BL投射神经元和中间神经元的放电频率分别足(0.32±0.04)Hz和(0.53±0.12)Hz,与正常大鼠相比无显著差异.在正常大鼠,所有投射神经元呈现爆发式放电;94%的中间神经元为爆发式放电,6%为不规则放电.在6.OHDA损毁大鼠,85%的投射神经元呈现爆发式放电,15%为不规则放电;86%的中间神经元为爆发式放电,14%为不规则放电,与正常大鼠相比无显著差别.静脉给予0.1 mg/kg体重的WAY-100635不改变正常大鼠和6-OHDA损毁人鼠BL投射神经元和中间神经元的放电频率.然而,0.5 mg/kg体重的WAY-100635却显著降低正常大鼠BL投射神经元的平均放电频率(P<0.01),明显增加6-OHDA损毁大鼠BL投射神经元的平均放电频率(P<0.004).高剂量WAY-100635不影响正常大鼠和6-OHDA损毁大鼠BL中间神经元的平均放电频率.结果表明,黑质多巴胺能损毁后内在和外在的传入调节BL神经元的活动,在正常大鼠和6-OHDA损毁大鼠5-HT1A 受体调节投射神经元的活动,并且在6-OHDA损毁大鼠WAY-100635诱发投射神经元平均放电频率增加.结果提示,5-HT1A 受体在帕金森病情感性症状的产生中起重要作用.     

阴虚动风证帕金森病异动症模型大鼠的氧化应激反应及复方地黄方的干预作用

目的探讨阴虚动风证帕金森病异动症(LID)大鼠氧化应激反应及复方地黄方的干预作用。方法采用6-羟基多巴胺(6-OHDA)偏侧损毁黑质制备帕金森病大鼠模型,进一步腹腔注射左旋多巴+苄丝肼(50 mg/kg左旋多巴和12.5 mg/kg苄丝肼)制备阴虚动风证帕金森病LID大鼠模型,并随机分为LID组、复方地黄方组,另取正常对照组、假手术组大鼠。每组6只。分别在4周、6周后进行神经行为学检测后,取纹状体,应用比色法分别测定各组大鼠纹状体内SOD、MDA、GSH、GSH-Px的含量。结果阴虚动风证帕金森病LID模型组大鼠纹状体内SOD、GSH、GSH-Px的含量均明显的减少,MDA的含量呈增加的趋势;而复方地黄方组大鼠纹状体内SOD、GSH、GSH-Px的含量均呈现增加的趋势,且随治疗时间的延长增加趋势更明显,MDA的含量呈现减少的趋势,且随治疗时间的延长减少的趋势更明显。结论复方地黄方较好地改善阴虚动风证LID大鼠的氧化应激反应,复方地黄方干预LID模型大鼠可能是通过清除自由基,减轻对细胞的损伤从而缓解帕金森病LID的症状。     

In Vivo Stimulation of D1 Receptors Increases the Phosphorylation of Proteins in the Striatum

In vivo changes in levels of DARPP-32 [dopamine (DA)- and cyclic AMP-regulated phosphoprotein, Mr = 32,000] protein phosphorylation in response to DA agonists in the rat striatum were measured using a novel assay that combines the benefits of rapid quenching of enzyme activity by focused microwave irradiation with a back-phosphorylation assay. The basal level of phospho-DARPP-32 was 5.6% of total DARPP-32. Injections of L-3,4-dihydroxyphenylalanine (100 mg/kg) increased this level to 44.4%. This effect was not as great if focused microwave irradiation was not used. The D1-specific agonist SKF 38393 (10 mg/kg) increased the level of phospho-DARPP-32 to 36.4%. A further modification of the back-phosphorylation assay was used to detect other phosphoproteins that appear to be regulated by DA. These results establish an assay for in vivo studies of postsynaptic responses involving second messengers in the DA system and provide direct in vivo evidence for the hypothesis that stimulation of D1 receptors increases the phosphorylation of DARPP-32, as well as several other proteins.     

Chronic Treatment of Rats with SCH-23390 or Raclopride Does Not Affect the Concentrations of DARPP-32 or Its mRNA in Dopamine-Innervated Brain Regions

DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein, Mr = 32,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) is a neuronal phosphoprotein that is enriched in neurons which possess dopamine D1 receptors, particularly striatonigral neurons. In rat brain slices, the phosphorylation state of DARPP-32 is regulated by dopamine, acting through the dopamine D1 receptor and the adenylyl cyclase system. This study reports that chronic blockade (21 days) of either dopamine D1 receptors by SCH-23390 or dopamine D2 receptors by raclopride does not affect the concentrations of DARPP-32 in specific rat brain regions (striatum, thalamus, hippocampus, frontal cerebral cortical pole). Northern blot analysis indicates that the steady-state level of DARPP-32 mRNA in striatum is also unchanged by these treatments.     

Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors

Neurotensin modulates dopaminergic transmission in the nigrostriatal system. DARPP-32, a dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa, is phosphorylated on Thr34 by cAMP-dependent protein kinase, resulting in its conversion into a potent inhibitor of protein phosphatase-1 (PP 1). Here, we examined the effect of neurotensin on DARPP-32 Thr34 phosphorylation using mouse neostriatal slices. Neurotensin stimulated DARPP-32 Thr34 phosphorylation by 4-7-fold with a K(0.5) of approximately 50 nM. The effect of neurotensin was antagonized by a combined neurotensin receptor type-1 (NTR1)/type-2 (NTR2) antagonist, SR142948. It was not antagonized by a NTR1 antagonist, SR48692 or by a NTR2 antagonist, levocabastine; neither was it antagonized by the two combined. Pretreatment with TTX or cobalt abolished the effect of neurotensin. The effect of neurotensin was antagonized by a dopamine D1 antagonist, SCH23390, and by ionotropic glutamate receptor antagonists, MK801 and CNQX. These results indicate that neurotensin stimulates the release of dopamine from nigrostriatal presynaptic terminals in an NMDA receptor- and AMPA receptor-dependent manner, leading to the increase in DARPP-32 Thr34 phosphorylation. Neurotensin stimulated the phosphorylation of Ser845 of the AMPA receptor GluR1 subunit in wild-type mice but not in DARPP-32 knockout mice. Thus, neurotensin, by stimulating the release of dopamine, activates the dopamine D1-receptor/cAMP/PKA/DARPP-32/PP 1 cascade.     

DARPP-32 Expression in Rat Brain After an Inhibitory Avoidance Task

Step-down inhibitory avoidance (IA) is usually acquired in one single trial, which makes it ideal for studying processes initiated by training, uncontaminated by prior or further trials, rehearsals, or retrievals. Biochemical events in the hippocampus related to long-term memory (LTM) formation have been extensively studied in rats using a one trial step-down IA task. DARPP-32 (dopamine and cAMP regulated phosphoprotein of Mr 32 kDa) is a cytosolic protein that is selectively enriched in medium spiny neurons in the neostriatum. It has been shown that activation of DARPP-32 and the resultant inhibition of PP-1 activity is critical for the expression of two opposing forms of brain synaptic plasticity, striatal LTD and LTP. Both forms of plasticity are also critically linked to the activation of DA receptors. It has been shown with studies in DARPP-32 KO mice an important role of this protein in mediating the effects of DA on long term changes in neuronal excitability and to our knowledge, no studies have examined the effect of IA task on DARPP-32 expression. In order to demonstrate changes in the protein expression profile we analyzed DARPP-32 levels in the striatum, prefrontal cortex (PFC), hippocampus and entorhinal cortex of Wistar rats after step-down IA learning. Our results showed that IA induced changes on DARPP-32 expression in striatum and hippocampus. DARPP-32 expression changes corroborate with changes in expression and phosphorylation of CREB, NMDA, AMPA after IA that has been reported. These changes suggest that DARPP-32 might play a central role in the IA, as previously described as an integrator of the dopaminergic signal.     

Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro

Brain-derived neurotrophic factor (BDNF) regulates several properties of striatal dopaminoceptive medium-sized spiny neurons (MSNs) in vivo and in vitro, including expression levels of DARPP-32 (dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein, 32 kDa). DARPP-32 is expressed in 96% of the MSNs, and is a key modulator of dopamine actions. We investigated the intracellular signal transduction pathways activated by BDNF in MSNs and via which BDNF induces DARPP-32 expression. We found that phosphorylation of the cyclic AMP response element binding protein (CREB) is only transiently increased following stimulation of MSNs by BDNF, whereas increased phosphorylation of the extracellular signal regulated kinases 1 and 2 (Erk1/2) and Akt is sustained for longer than 4 h. Treatment of cultures with inhibitors of mitogen-activated protein kinase kinase (MEK) or phosphatidylinositide 3-kinase (PI3K) showed that the majority of the BDNF-induced increase in DARPP-32 requires the PI3K pathway. We also found that inhibition of PI3K reduces BDNF-induced Erk phosphorylation, indicating that cross-talk between these pathways may play a prominent role in MSNs.     

DARPP-32 and NCS-1 Expression is not Altered in Brains of Rats Treated with Typical or Atypical Antipsychotics

Dopamine-mediated neurotransmission imbalances are associated with several psychiatry illnesses, such as schizophrenia. Recently it was demonstrated that two proteins involved in dopamine signaling are altered in prefrontal cortex (PFC) of schizophrenic patients. DARPP-32 is a key downstream effector of intracellular signaling pathway and is downregulated in PFC of schizophrenic subjects. NCS-1 is a neuronal calcium sensor that can inhibit dopamine receptor D₂ internalization and is upregulated in PFC of schizophrenic subjects. It is well known that dopamine D₂ receptor is the main target of antipsychotic. Therefore, our purpose was to study if chronic treatment with typical or atypical antipsychotics induced alterations in DARPP-32 and NCS-1 expression in five brain regions: prefrontal cortex, hippocampus, striatum, cortex and cerebellum. We did not find any changes in DARPP-32 and NCS-1 protein expression in any brain region investigated.     

Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice

Methylphenidate (MPH), a dopamine uptake inhibitor, is the most commonly prescribed drug for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children. We examined the effect of MPH on dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) phosphorylation at Thr34 (PKA-site) and Thr75 (Cdk5-site) using neostriatal slices from young (14-15- and 21-22-day-old) and adult (6-8-week-old) mice. MPH increased DARPP-32 Thr34 phosphorylation and decreased Thr75 phosphorylation in slices from adult mice. The effect of MPH was blocked by a dopamine D1 antagonist, SCH23390. In slices from young mice, MPH did not affect DARPP-32 phosphorylation. As with MPH, cocaine stimulated DARPP-32 Thr34 phosphorylation in slices from adult, but not from young mice. In contrast, a dopamine D1 agonist, SKF81297, regulated DARPP-32 phosphorylation comparably in slices from young and adult mice, as did methamphetamine, a dopamine releaser. The results suggest that dopamine synthesis and the dopamine transporter are functional at dopaminergic terminals in young mice. In contrast, the lack of effect of MPH in young mice is likely attributable to immature development of the machinery that regulates vesicular dopamine release.     

Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons

Nicotine, acting on nicotinic acetylcholine receptors (nAChRs) expressed at pre-synaptic dopaminergic terminals, has been shown to stimulate the release of dopamine in the neostriatum. However, the molecular consequences of pre-synaptic nAChR activation in post-synaptic neostriatal neurons are not clearly understood. Here, we investigated the effect of nAChR activation on dopaminergic signaling in medium spiny neurons by measuring phosphorylated DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 (the PKA-site) in mouse neostriatal slices. Nicotine produced dose-dependent responses, with a low concentration (1 microm) causing a sustained decrease in DARPP-32 Thr34 phosphorylation and a high concentration (100 microm) causing a transient increase in DARPP-32 Thr34 phosphorylation. Depending on the concentration of nicotine, either dopamine D2 or D1 receptor signaling was predominantly activated. Nicotine at a low concentration (1 microm) activated dopamine D2 receptor signaling in striatopallidal/indirect pathway neurons, likely by activating alpha4beta2* nAChRs at dopaminergic terminals. Nicotine at a high concentration (100 microm) activated dopamine D1 receptor signaling in striatonigral/direct pathway neurons, likely by activating (i) alpha4beta2* nAChRs at dopaminergic terminals and (ii) alpha7 nAChRs at glutamatergic terminals, which, by stimulating the release of glutamate, activated NMDA/AMPA receptors at dopaminergic terminals. The differential effects of low and high nicotine concentrations on D2- and D1-dependent signaling pathways in striatal neurons may contribute to dose-dependent actions of this drug of abuse.